Sanofi SA (EPA:SAN) has been assigned a €97.00 ($114.12) price target by stock analysts at Berenberg Bank in a research report issued on Thursday. The firm presently has a “neutral” rating on the stock.

Other research analysts have also recently issued research reports about the stock. J P Morgan Chase & Co restated a “neutral” rating on shares of Sanofi SA in a report on Thursday. S&P Global set a €90.00 ($105.88) price objective on shares of Sanofi SA and gave the company a “neutral” rating in a report on Monday, July 31st. Sanford C. Bernstein set a €90.00 ($105.88) price objective on shares of Sanofi SA and gave the company a “neutral” rating in a report on Monday, July 31st. Goldman Sachs Group, Inc. (The) set a €82.00 ($96.47) price objective on shares of Sanofi SA and gave the company a “neutral” rating in a report on Wednesday, July 26th. Finally, Jefferies Group LLC set a €87.00 ($102.35) price objective on shares of Sanofi SA and gave the company a “neutral” rating in a report on Thursday, August 24th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and five have issued a buy rating to the stock. Sanofi SA has an average rating of “Hold” and a consensus price target of €88.12 ($103.67).

WARNING: “Sanofi SA (SAN) Given a €97.00 Price Target at Berenberg Bank” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2017/11/02/sanofi-sa-san-given-a-97-00-price-target-at-berenberg-bank.html.

Sanofi SA Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi SA (EPA:SAN)

Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.